RESUMO
RESUMEN Objetivo: Describir y discutir la evidencia actual sobre la relación entre desempeño cognitivo, trastorno afectivo bipolar (TAB) y síndrome metabólico (SM). Métodos: Se buscaron artículos relacionados en distintas bases de datos bibliográficas (MEDLINE, EMBASE, Scielo), y con los artículos seleccionados se realizó una revisión narrativa de la literatura. Resultados: Hasta el momento no se ha estudiado ampliamente el SM en el TAB, pero sí hay datos importantes en la asociación con las variables metabólicas individuales. Se señala que la obesidad de los pacientes con TAB se asocia con peor desempeño en memoria verbal, velocidad de procesamiento psicomotor y atención sostenida. Parecería que la hipertrigliceridemia de los pacientes con TAB está en relación con deterioro en la función ejecutiva, y la hipertensión arterial, con el deterioro en la función cognitiva general. Conclusiones: Aunque algunas variables del SM se asocian con peor desempeño cognitivo en pacientes con TAB, faltan estudios para establecer con precisión la naturaleza de esta relación.
ABSTRACT Objective: To describe and discuss current evidence on the relationship between cognitive performance, Bipolar Affective Disorder (BAD) and Metabolic Syndrome (MS). Methods: We searched for related articles in different bibliographic databases (MEDLINE, EMBASE, Scielo) and performed a narrative review of the literature with the selected articles. Results: To date, evidence has not been conclusive and the effect of MS on BD has not been widely studied, but important correlations have been observed with individual metabolic variables. It is suggested that obesity in patients with BAD is associated wotj worse performance in verbal memory, psychomotor processing speed, and sustained attention. Hypertriglyceridemia in patients with BAD appears to be associated with a lower score in executive function tasks; hypertension appears to be associated with impairment in overall cognitive function. Conclusions: Despite the associations between MS and poor cognitive performance in patients suffering from BAD, more studies are required to precisely determine how these variables are related to each other.
Assuntos
Humanos , Masculino , Feminino , Adulto , Transtorno Bipolar , Cognição , Síndrome Metabólica , Estresse Psicológico , Transtornos do Humor , MemóriaRESUMO
OBJECTIVE: To describe and discuss current evidence on the relationship between cognitive performance, Bipolar Affective Disorder (BAD) and Metabolic Syndrome (MS). METHODS: We searched for related articles in different bibliographic databases (MEDLINE, EMBASE, Scielo) and performed a narrative review of the literature with the selected articles. RESULTS: To date, evidence has not been conclusive and the effect of MS on BD has not been widely studied, but important correlations have been observed with individual metabolic variables. It is suggested that obesity in patients with BAD is associated wotj worse performance in verbal memory, psychomotor processing speed, and sustained attention. Hypertriglyceridemia in patients with BAD appears to be associated with a lower score in executive function tasks; hypertension appears to be associated with impairment in overall cognitive function. CONCLUSIONS: Despite the associations between MS and poor cognitive performance in patients suffering from BAD, more studies are required to precisely determine how these variables are related to each other.
Assuntos
Transtorno Bipolar/psicologia , Cognição , Síndrome Metabólica/psicologia , Transtorno Bipolar/complicações , Humanos , Síndrome Metabólica/complicaçõesRESUMO
Resumen Introducción y objetivos: La apatía, entendida como un déficit para el inicio y el mantenimiento de la acción, es un síntoma que afecta a los pacientes con diversas enfermedades psiquiátricas y neuropsiquiátricas, como demencias, secuelas de traumatismo craneal, esquizofrenia y depresión y enfermedad de Parkinson (EP). La apatía afecta negativamente a la funcionalidad y la calidad de vida de los pacientes con EP y es fuente importante de estrés del cuidador. El tratamiento farmacológico de la apatía en la EP es el foco de esta revisión sistemática. Métodos: Se realizó una búsqueda con selección sistemática de artículos originales sobre el tratamiento de la apatía en la EP en diferentes bases de datos, se consolidaron los resultados, se realizó lectura crítica de los artículos y se discutieron los hallazgos. Resultados: Se incluyeron 11 estudios. Aunque algunos mostraron eficacia, todos presentaban limitaciones metodológicas importantes, que no permitían considerar que se pueda tomar en cuenta los resultados de dichos ensayos clínicos como evidencia para guiar las decisiones clínicas. Conclusiones: Hasta el momento no se puede ofrecer recomendaciones basadas en la evidencia para el tratamiento farmacológico de la apatía en la EP. Hacen falta estudios con mejor calidad metodológica. Es un área de investigación potencialmente fructífera y muy necesaria para los pacientes con EP y sus familiares.
Abstract Introduction and objectives: Apathy, defined as a deficit for initiating and maintaining action, is a symptom affecting patients with diverse psychiatric and neuropsychiatric diseases, including dementia, sequelae of traumatic brain injury, schizophrenia, depression, and Parkinson's disease (PD). Apathy negatively affects function and quality of life of PD patients, and it is an important cause of caregiver's distress. The pharmacological treatment of apathy in PD is the focus of this systematic review. Methods: A comprehensive search and systematic selection was performed in different databases of original research papers on the treatment of apathy in PD. The results were then consolidated, and a critical analysis was made of the research papers. The results are then discussed according to the methodological standards for systematic reviews of the literature. Results: A total of 11 studies were included. Although some studies showed efficacy, all of them had important methodological limitations that hampered the interpretation of results. The results of the examined studies cannot be considered as evidence for guiding clinical decisions. Conclusions: So far, no evidence-based recommendations can be offered for the treatment of apathy in PD. More studies with better methodological quality are needed. It is a potentially fruitful area for research and one badly needed by both PD patients and their caregivers.
Assuntos
Humanos , Masculino , Feminino , Doença de Parkinson , Terapêutica , Apatia , Qualidade de Vida , Esquizofrenia , Afeto , Demência , Depressão , Tratamento Farmacológico , Transtornos Mentais , MétodosRESUMO
INTRODUCTION AND OBJECTIVES: Apathy, defined as a deficit for initiating and maintaining action, is a symptom affecting patients with diverse psychiatric and neuropsychiatric diseases, including dementia, sequelae of traumatic brain injury, schizophrenia, depression, and Parkinson's disease (PD). Apathy negatively affects function and quality of life of PD patients, and it is an important cause of caregiver's distress. The pharmacological treatment of apathy in PD is the focus of this systematic review. METHODS: A comprehensive search and systematic selection was performed in different databases of original research papers on the treatment of apathy in PD. The results were then consolidated, and a critical analysis was made of the research papers. The results are then discussed according to the methodological standards for systematic reviews of the literature. RESULTS: A total of 11 studies were included. Although some studies showed efficacy, all of them had important methodological limitations that hampered the interpretation of results. The results of the examined studies cannot be considered as evidence for guiding clinical decisions. CONCLUSIONS: So far, no evidence-based recommendations can be offered for the treatment of apathy in PD. More studies with better methodological quality are needed. It is a potentially fruitful area for research and one badly needed by both PD patients and their caregivers.
